Objective: We have recently reported that prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass grafting (CABG) surgery. Because fibrinogen for the first time was administered to patients without hereditary fibrinogen deficiency or ongoing bleeding, a detailed analysis of the effects of fibrinogen concentrate on biomarkers of coagulation, fibrinolysis, and platelet function was performed. Methods: Twenty CABG patients with preoperative plasma fibrinogen levels <3.8 g/L were included in a prospective study. Patients were randomized to preoperative infusion of 2 g fibrinogen concentrate (fibrinogen group) or no infusion (control group). Activated partial thromboplastin time (aPTT), prothrombin time, activated clotting time, and plasma concentrations of fibrinogen, antithrombin, thrombinÀantithrombin complex, prothrombin fragment 1.2, and D-dimer, thromboelastometry, platelet count, and platelet aggregometry were analyzed before and 15 minutes after infusion, and 2 and 24 hours after surgery. Results: Fifteen minutes after infusion of fibrinogen concentrate, fibrinogen plasma levels increased by 0.6 + 0.2 g/L (P < .001 between groups), and induced minimal changes in aPTT and plasma levels of antithrombin, while remaining variables remained unchanged. After surgery, fibrinogen levels no longer differed between groups. D-dimer was significantly higher after surgery in the fibrinogen group (P ¼ .03), while none of the other markers were statistically different between groups. Conclusions: Infusion of 2 g fibrinogen to cardiac surgery patients, without hereditary or acquired fibrinogen deficiency or ongoing bleeding, results in no or minimal changes in biomarkers reflecting coagulation and platelet function. An increased release of fibrin degradation products was detected after surgery in fibrinogen-treated patients.
Introduction
Fibrinogen is a key factor for coagulation, fibrinolysis, and cellular blood matrix interactions. 1 Infusion of fibrinogen concentrate is used to treat hereditary fibrinogen deficiency 2, 3 and has also been shown to reduce bleeding and transfusion requirements during and after major surgery. [4] [5] [6] [7] The preoperative plasma fibrinogen level has been reported to correlate to blood loss after cardiac surgery, [8] [9] [10] [11] [12] although there are contradictory reports. [13] [14] [15] The correlation suggests that the fibrinogen concentration, even within the normal reference range, is a limiting factor for postoperative hemostasis and raises the question whether prophylactic treatment with fibrinogen concentrate may reduce postoperative bleeding and transfusion requirements. Our group recently performed a prospective randomized controlled pilot study to test this hypothesis on coronary artery bypass graft (CABG) surgery patients with endogenous fibrinogen plasma levels in the lower normal range ( 3.8 g/L). 5 The main results of the pilot study were a significant reduction in postoperative blood loss (À32%), better maintained hemoglobin levels in the fibrinogen group, and a tendency toward a reduction in blood transfusions, without evidence of increased incidence of prothrombotic events. 5 As far as we know, this was the first time fibrinogen concentrate was administered prophylactically to humans without hereditary or acquired fibrinogen deficiency or as treatment for ongoing bleeding. Therefore, a comprehensive test series was applied to determine the effects of fibrinogen concentrate infusion in patients with normal hemostasis. Thus, the aim of the current study, based on the same patient material as in the previous publication, 5 was to investigate the effect of fibrinogen concentrate infusion on biomarkers of coagulation, fibrinolysis, and platelet function in cardiac surgery patients, without known fibrinogen deficiency disorder or ongoing bleeding.
Material and Methods Patients and Study Design
A detailed description of the study rationale, design, patients, and clinical management has been presented previously. 5 Twenty elective first-time CABG patients with a preoperative plasma fibrinogen level of 3.8 g/L were included in a prospective randomized controlled study after informed written consent. Fifty-one patients were screened regarding plasma concentration of fibrinogen to obtain the 20 patients that were included in the study. Patient characteristics are given in Table 1 . Predefined exclusion criteria were liver or kidney disease, bleeding disorder, and a surgical source of bleeding at acute reexploration. Patients were randomized to either infusion of 2 g fibrinogen concentrate (Haemocomplettan 1 , CSL Behring, Marburg, Germany) or no infusion before the operation.
Baseline blood sampling was conducted from a peripheral venous catheter immediately after arrival to the operating room. Following this, the patient received an arterial line. After anesthesia was induced, central venous lines were inserted. The second sample (after infusion) was drawn from a central venous line. Fibrinogen concentrate was prepared according to the instructions from the manufacturer and infused intravenously in a central venous catheter during approximately 5 minutes after the baseline measurements. Blood samples were collected 15 minutes after completed infusion, and 2 and 24 hours after surgery. Control patients did not receive any placebo infusion. However, the second measurement is referred to as ''after infusion'' in both groups. The patients received heparin (300 units/kg body weight) to maintain an activated clotting time of >480 seconds during cardiopulmonary bypass (CPB). After CPB, the heparin was reversed by the administration of protamine (1 mg protamine/100 units heparin) to an ACT of <130 seconds. Aspirin was not discontinued before surgery. Clopidogrel was discontinued at least 5 days before surgery. Neither aprotinin nor tranexamic acid was used in any of the study patients. The Swedish Medical Product Agency and the Regional Research Ethics Committee approved the study protocol.
Analyses
The following biomarkers reflecting coagulation were analyzed: fibrinogen, activated partial thromboplastin time (aPTT), activated coagulation time (ACT), prothrombin time (PT), antithrombin, thrombinÀantithrombin complex (TAT), prothrombin fragment 1.2 (F1.2) and rotational thromboelastometry (Rotem, Pentapharm, Munich, Germany). Plasma D-dimer was analyzed as a marker of fibrin degradation and fibrinolysis. Platelets were assessed by analyzing platelet count and impedance aggregometry. All analyses except platelet impedance aggregometry were performed in an accredited university hospital laboratory.
Plasma fibrinogen concentration was determined according to the method by Clauss 16 with the use of an assay in which excess thrombin is added to diluted low fibrinogen containing plasma to determine the amount of clottable protein (STA-FIB 2, Diagnostica Stago, Asnieres, France). Reference range is 2.0 to 4.5 g/L. Activated partial thromboplastin time was analyzed by a 1-stage process in which platelet-poor plasma was incubated with aPTT reagent (cephalin reagent with particulate silica activator), and coagulation was initiated by the addition of CaCl 2 (STA-PTT Automate 5, Diagnostica Stago, Asnieres, France). Reference range is 30 to 42 seconds. Hematocrit (%) was measured with standard clinical methods. ACT (seconds) was measured with a Hemochron Jr Signature þ point-ofcare device (ITC, Edison, New Jersey). Prothrombin time was analyzed according to the Owren method 17 using STA-R with Stago Prothrombin Complex Assay (Diagnostica Stago) and reported as the international normalized ratio (INR). Antithrombin was measured by STA-R using the STA-StachromAT III reagent (Diagnostica Stago). Reference range is 0.80 to 1.20 kilo international units/litre (kIU/L). Throm-binÀantithrombin complex and F1.2 were measured using enzyme-linked immunosorbent assay (ELISA) methods with the iEMS Reader with Enzygnost* TAT microreagent, reference range 1.0 to 4.1 mg/L, and Enzygnost*F1þ2 (monoclonal) reagent, reference range 70 to 230 pmol/L, respectively (both Dade Behring AB, Skärholmen, Sweden). The TAT and F1.2 assay kits have variation coefficients within each analyzed series of 4% to 6% and 3.6% to 5.5%, respectively. D-Dimer was analyzed with a latex agglutination method by STA-R using STA-LiatestD-DI reagent, reference interval 0.5 mg/L (Diagnostica Stago). The technical details of rotational whole blood thromboelastometry (Rotem, Pentapharm) have been described previously. 18 Four parallel channels (INTEM, EXTEM, FIBTEM, and HEPTEM) were used. INTEM analyzes the internal pathway of the coagulation cascade with ellagic acid as activator, and EXTEM the external pathway with tissue factor as activator. In the FIBTEM analysis, the fibrinogen component (concentration and function of clot polymerization) of coagulation is evaluated after the contribution of platelets is inhibited by the addition of cytochalasin D. In HEPTEM, heparinase is added to evaluate the effect of heparin. In each of these 4 channels, the following variables were assessed: clotting time (CT), clot formation time (CFT), and maximum clot firmness (MCF). HEPTEM was only analyzed in the 2 postoperative measurements because heparin was not administered before CPB.
Platelet impedance aggregometry was analyzed with a Multiplate platelet function analyzer (Dynabyte Medical, Munich, Germany), which analyses platelet aggregability in whole blood after the addition of different platelet receptor agonists. 19 In the current study adenosine diphosphate (ADP) was used as agonist with a concentration of 6.4 mmol/L. The ADP test is sensitive to clopidogrel, prazugrel, and other ADP receptor antagonists. The impedance is calculated as aggregation units Â minutes (AU Â min) and reported as area under the curve (AUC). The manufacturer's reference range for normal participants in ADP is AUC 383 to 848.
Statistics
All data are presented as mean + standard deviation. A P value of <.05 was considered statistically significant. Changes in variables after infusion and 2 and 24 hours after surgery compared to baseline, respectively, were calculated and given as a D (delta) value. Group comparisons of absolute values and D values were made with the Student t test for continuous variables. Changes from baseline within a group were analyzed with paired t test. For group comparisons of variables analyzed at more than one occasion, analysis of variance (ANOVA) for repeated measurements was used, followed by Student t test if the ANOVA (group or interaction between group and time) indicated a significant difference (P < .05). Correlations between plasma levels of fibrinogen and biomarkers of coagulation and fibrinolysis were analyzed using Pearson test. Plasma concentrations of fibrinogen, D-dimer, antithrombin, TAT, and F1.2 were adjusted for hematocrit, due to the large inter-individual differences in perioperative hemodilution, which in the current study ranged from 23% to 51%. The adjustments were performed according to the formula: adjusted concentration ¼ measured concentration Â (standard hematocrit/measured hematocrit) using 40% as a standard hematocrit. 20 
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Results

Baseline Variables
At baseline, there were no statistical differences in age, gender distribution, body mass index (BMI), serum creatinine levels, liver function tests, smoking habits, or preoperative anticoagulation treatment between the 2 groups (Table 1 ).
Immediate Effects of Fibrinogen Concentrate Infusion (Baseline vs 15 Minutes After Completed Infusion)
Mean baseline fibrinogen level was 2.9 + 0.2 g/L (range 2.5-3.4 g/L) and 3.0 + 0.3 g/L (range 2.4-3.7 g/L) in the control group ( Table 2) . Infusion of 2 g fibrinogen concentrate, corresponding to 18 to 34 mg/kg body weight, increased plasma fibrinogen levels by 0.6 + 0.2 g/L (P < .001). Individual fibrinogen plasma concentrations are given in Figure 1 . After fibrinogen infusion, there was a slight but statistically significant decline in plasma levels of antithrombin (À0.02 + 0.02 vs þ0.01 + 0.03 kIU/L, P ¼ .012 between the groups) and a small elevation in aPTT (þ0.7 + 0.8 vs À0.7 + 1.7 seconds, P ¼ .03 between the groups, Table 2 ). Thromboelastometry values remained mainly unchanged after fibrinogen infusion (Table 3) , whereas platelet aggregability decreased in both groups but without intergroup differences (Table 3 ). There were no correlation between fibrinogen levels and any of the markers of coagulation, fibrinolysis, and platelet function, not before neither after the fibrinogen infusion.
Postoperative Effects of Fibrinogen-Measurements After Infusion vs 2 and 24 Hours After Surgery
Two hours after surgery, the plasma fibrinogen levels were lower than that before surgery but not significantly different between the 2 groups (Table 4 ). Twenty-four hours after surgery, the plasma fibrinogen level was markedly elevated in both groups without intergroup differences. Throm-binÀantithrombin complex and F1.2 levels increased as expected in both groups after surgery but without significant intergroup differences. D-dimer levels were significantly elevated 2 hours after surgery in both groups (Figure 2 ). ANOVA for repeated measurements indicated significantly higher Ddimer levels in the fibrinogen group (P ¼ .03). Antithrombin Figure 1 . Individual plasma fibrinogen concentrations in 10 patients receiving 2 g of fibrinogen before coronary artery bypass surgery. Fibrinogen plasma concentration was measured at baseline, after infusion, and 2 and 24 hours after surgery. increased 24 hours after surgery in both groups without intergroup differences. Thromboelastometry values and platelet aggregability did not differ between the groups, 2 and 24 hours after surgery (Table 5 ). There were no detectable correlations between fibrinogen levels and any of the markers of coagulation, fibrinolysis, and platelet function.
Discussion
The major finding of the current study was that infusion of 2 g fibrinogen to cardiac surgery patients, without hereditary or acquired fibrinogen deficiency or ongoing bleeding, results in no or minimal changes in biomarkers reflecting coagulation, fibrinolysis, and platelet function. Recently published results suggest that the plasma fibrinogen level may be a limiting factor for postoperative hemostasis in patients undergoing CABG. [8] [9] [10] [11] A subsequent randomized pilot study performed by our group demonstrated that a preoperative, prophylactic infusion of fibrinogen to CABG patients significantly reduced postoperative bleeding without evidence of an increased incidence of thromboembolic events, such as graft occlusion, myocardial infarction, and pulmonary embolism. 5 From a safety point of view, we found it also essential to thoroughly monitor the effect of fibrinogen concentrate on markers of coagulation, fibrinolysis, and platelet function, although it should be stressed that the safety data are of preliminary nature due to the small sample size.
The study included a control group to more accurately analyze the effects of fibrinogen infusion. The preoperative period is dynamic and without a control group, potential changes in coagulation factors in the fibrinogen group might be interpreted as effects of fibrinogen, when they may instead be related to for example anesthesia, arterial and vein puncture, catheterization, or infusion of crystalloid fluids. In addition, plasma concentrations of coagulation factors are normally affected by hemodilution secondary to fluid replacement therapy. To correct for inter-and intra-individual differences in hemodilution, plasma concentrations of coagulation factors were adjusted to the patient's actual hematocrit at each point of measurement.
In general, fibrinogen concentrate infusion induced no or minimal changes in the analyzed markers of coagulation, fibrinolysis, and platelet function. Regarding immediate effects, there was an expected increase in plasma fibrinogen levels in the fibrinogen group (Table 2, Figure 1 ). Antithrombin, an anticoagulant factor in human blood plasma, which is usually decreased during and after CPB, 21 was marginally but significantly decreased in the fibrinogen group compared to the control group. However, the range for each group was rather similar after infusion (0.75-0.96 kIU/L in the fibrinogen group vs 0.8 -1.01 kIU/L in the control group) as well as before infusion (0.81-1.06 kIU/L in the fibrinogen group vs 0.78-1.09 kIU/L in the control group), and because both measurements were made before heparinization, the biological meaning of this variation is likely irrelevant. ThrombinÀantithrombin complex and F1.2, molecular markers of thrombin activity and generation, were discretely elevated in both groups, somewhat more markedly among controls, but there was no significant difference between the groups. It is possible that the vascular trauma (arterial line and central venous line insertion) between the 2 first measurements contribute to the elevations. Discrete variations in TAT and F1.2 might also be due to sampling technique and the analysis itself rather than increased thrombin generation, 22 and because the differences were minor the former cannot be ruled out. In addition, no major surgical trauma had yet occurred that would stimulate thrombin generation to a larger extent.
Since both in vitro and in vivo studies have demonstrated significantly improved clot stability after fibrinogen replenishment, 4, 23, 24 and a close correlation between fibrinogen levels and FIBTEM MCF has been shown, 25 an enhanced FIBTEM MCF could have been expected immediately after fibrinogen infusion. However, there was no difference between the groups which may be explained by the study design. In the current study, the patients had normal hematocrit and normal FIBTEM at the time of fibrinogen administration. In contrast, in the studies where fibrinogen improved clot stability, the samples were subjected to hemodilution before analysis, either in vitro 23, 24 or in vivo. 4 An alternative explanation is that although the increase in plasma concentration in the fibrinogen group after infusion was statistically significant, the increase is still rather small (mean increase 0.6 g/L) and the FIBTEM test may not be sensitive enough to detect the increased levels.
In the current study, fibrinogen was administered prophylactically before CPB. Another approach would be to administer fibrinogen or any other hemostatic substance after CPB in patients with ongoing bleeding. This concept was recently tested with recombinant factor VII (rFVIIa). 26 In the study, rFVIIa reduced reexploration for bleeding and transfusion requirements but was also associated with an increased incidence of severe complications, including stroke. The study underlines the risks associated with artificially altered hemostasis and the thin line between hemostasis and thrombosis.
Our second aim was to compare the fibrinogen group and the control group in relation to completed surgery. In this analysis, we used measurements after infusion as baseline and compared this to measurements 2 and 24 hours after surgery. The elevation in plasma fibrinogen after infusion was no longer significantly different between the groups 2 and 24 hours after surgery. Plasma concentrations of D-dimer were, as expected, 27 increased after surgery compared to the preoperative levels (Table 4, Figure 2 ). Furthermore, D-dimer was significantly higher in the fibrinogen group 2 hours after surgery compared to the control group (P ¼ .03, ANOVA for repeated measurements, Figure 2 ). The results may indirectly indicate an increased fibrin generation in the fibrinogen group during the preceding period of time, that is during surgery, which may be partly responsible for the reduced postoperative blood loss in this group. Alternatively, it is possible that the increased level of D-dimer in the fibrinogen group reflects increased fibrinolysis rather than increased fibrin production. The current study cannot discriminate between these 2 mechanisms. The main limitation of the study is the low number of participants (n ¼ 20). A statistical type II error cannot be ruled out and the results should therefore be considered preliminary. It is possible that changes in hemostatic factors would have been detected in a larger number of patients. The study size was limited as a safety precaution because this was the first study on the subject and the authorities restricted the allowed number of participants. The standardized dose of fibrinogen (2 g) might be another limitation. A weight-adjusted dose was considered before the study was started but due to practical reasons and the absence of dosage recommendations, a standardized dose was chosen. Another limitation may be the number and choice of biomarkers. Other biomarkers may have yielded a different result. In the platelet aggregation test, only ADP was used as initiator. We acknowledge that this test can only partially assess platelet function. Furthermore, the biomarkers were not analyzed during surgery. Because there was a clear difference in postoperative bleeding between the groups, 5 one may speculate that there might be differences in the hemostatic variables during surgery, which were not detected by the pre-and postoperative measurements.
In conclusion, infusion of 2 g fibrinogen to cardiac surgery patients, without hereditary or acquired fibrinogen deficiency or ongoing bleeding, results in no or minimal changes in biomarkers reflecting coagulation, fibrinolysis, and platelet function.
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